As a proof-of-principle, it is notable that two of the targets of monoclonal antibodies currently being used or investigated for treatment of MS (VCAM1 - natalizumab, IL2RA - daclizumab) are implicated by GWAS [16]. This evidence concerns the gene IL2RA and myeloid sarcoma.